AGM Questions17 Dec 2025 15:24
FWIW, I have today given SBTX advance notice of some questions I intend to ask at the AGM. I believe they are polite, legitimate and even restrained – but no doubt they will find a way to reject them:
"Dear Ms Bertram,
I write as a courtesy to give advance notice of the questions I intend to ask at the Skinbiotherapeutics Plc AGM on 29 December. I trust that the Chairman will thus be able to give a considered answer at the meeting, or ahead of the meeting if he wishes. I sent you yesterday proof of my CREST shareholding in my Interactive Investor nominee account via a Letter of Representation and trust that will suffice for this purpose.
QUESTION IN ADVANCE #01
Given that the QCA Code guides companies not to retain the same independent chairman for longer than nine years and that the present chairman has been in office for longer than nine years, what are the exceptional circumstances that the company feels warrant this departure from the QCA guidance?
QUESTION IN ADVANCE #02
Given that the Board undertook a year ago to adopt QCA guidelines by re-electing directors annually, what are the changed circumstances which justify the recent decision to abandon this compliance and revert to a three-year re-election cycle?
QUESTION IN ADVANCE #03
Given the considerable barriers, both seasonal and geographical, to shareholder engagement at this and previous AGMs, will the Board undertake to convene future AGMs as hybrid meetings which, in addition to the physical meeting, will afford shareholders the opportunity to engage live with the proceedings via a streaming platform and also provide the functionality to ask questions and vote remotely? The Investor Meet Company has said that its existing annual contract with Skinbiotherapeutics Plc will allow this added functionality to be provided at no additional cost. I raised this question with Mr Ashman a year ago but still await an answer.
QUESTION IN ADVANCE #04
For much of the past year, I have received no acknowledgement of my occasional and legitimate emailed queries or telephone calls to Mr Ashman and the Skinbiotherapeutics Plc Investor Relations Desk – a complaint which has been echoed online by numerous other retail shareholders. If this indicates a lack of resources to process investor enquiries, will the Board undertake to expand this resource so that legitimate shareholder enquiries are answered in a timely fashion?
I trust that you will deal with questions before any votes are taken, in line with governance guidance.
Many thanks.
Best regards,"